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Reference miRNAs for colorectal 
cancer: analysis and verification of 
current data
E. Danese  1, A. M Minicozzi2, M. Benati1, E. Paviati1, G. Lima-Oliveira1, M. Gusella3,  
F. Pasini4, G. L Salvagno  1, M. Montagnana1 & G. Lippi  1
MicroRNAs (miRNAs) hold great promise in cancer research. The use of appropriate reference 
miRNAs for normalization of qPCR data is crucial for accurate expression analysis. We present here 
analysis and verification of current data, proposing a workflow strategy for identification of reference 
miRNAs in colorectal cancer (CRC). We performed a systematic review of studies aimed to identify 
stable reference miRNAs in CRC through high-throughput screening. Among the candidate miRNAs 
selected from the literature we excluded those predicted to target oncogenes or tumor suppressor 
gene. We then assessed the expression levels of the remaining candidates in exosomes, plasma and 
tissue samples from CRC patients and healthy controls. The expression stability was evaluated by 
box-plot, ∆Cq analysis, NormFinder and BestKeeper statistical algorithms. The effects of normalisers 
on the relative quantification of the oncogenic miR-1290 was also assessed. Our results consistently 
showed that different combinations of miR-520d, miR-1228 and miR-345 provided the most stably 
expressed reference miRNAs in the three biological matrices. We identified suitable reference miRNAs 
for future miRNA expression studies in exosomes plasma and tissues CRC samples. We also provided a 
novel conceptual framework that overcome the need of performing ex novo identification of suitable 
reference genes in single experimental systems.
MicroRNAs (miRNAs) are short non-coding RNA fragments involved in post-transcriptional regulation of gene 
expression. In physiological conditions, miRNAs regulate a kaleidoscope of biological pathways including cell 
differentiation, proliferation and survival. Changes in miRNA expression profiles are frequently associated with 
abnormal cellular functions. Different expression patterns have hence been observed in a variety of diseases, 
including cancer. MiRNAs play an important role in the multistep processes of carcinogenesis, by targeting either 
oncogenes or tumor suppressor genes. The current research based on miRNA expression has been broadened 
into many types of tumors. Among different malignancies, miRNA expression in colorectal cancer (CRC) has 
been deeply analyzed for establishing its potential role as diagnostic, prognostic and predictive tool1–5. Although 
several technologies have been used for enabling high-throughput and sensitive miRNA profiling, reverse tran-
scription quantitative real-time polymerase chain reaction (RT-qPCR) is still regarded as the method of choice 
due to higher sensibility and specificity. In qPCR experiments, data are usually reported as relative expression 
quantification, and the signal of the target miRNA in a treatment group is conventionally compared to that of an 
untreated control population. More specifically, the PCR-derived cycle threshold (Cq) of a target miRNA is com-
pared with that of a stably expressed endogenous miRNA obtained from the same sample. The difference between 
these values is referred to as the ∆Cq value. The process of normalization is required to reduce the potential bias 
attributable to sample-to-sample non-biological variations introduced throughout the total testing process, from 
sample preparation to amplification and analysis. Therefore, the ultimate purpose is to accurately distinguishing 
between biological changes and experimentally induced variation. The possibility to report data as ∆Cq value 
also enables a more reliable comparison of data obtained within the same experiment and even among different 
experiments.
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Due to the fact that an universal reference gene to be suitably used for all types of tissue does not exist so far, 
the normalization procedure has represented one of the most important and challenging issues in qPCR exper-
iments. A huge number of miRNA expression studies has been published, but many data have been recently 
questioned since the endogenous reference genes which are commonly used for normalization may be unsta-
bly and heterogeneously expressed6. It has also been emphasized that the use of an inaccurate procedure for 
normalization may be one of the most relevant causes of limited overlap between findings from similar studies 
in the same pathological condition. The most accurate approach recently endorsed entails a selection of stably 
expressed reference to be used in each specific experiment, according to the tissue of interest and by means of 
high-throughput technologies7, 8. Nevertheless, this approach is often difficult to carry out due to the substantial 
cost of microarray assays.
Many efforts in miRNA research are currently focused on developing a standardized procedure for data nor-
malization of miRNA expression, based on reference gene(s) selection. Due to the lack of universal consensus, 
some specific experimental workflows have been proposed9–12. Notably, Schwarzenbach and coauthors recently 
highlighted that research studies based on qPCR miRNA quantification for identifying candidate reference genes, 
should be anticipated by an extensive literature review of previous studies bas transcription polymerase chain ed 
on similar patient populations, on the analysis of the same biological matrix and using an identical process of 
sample management13. The suitability of using the identified miRNAs for a specific type of samples should then 
be validated in a sample subset.
Despite a large number of miRNA expression studies has been published in CRC patients, a critical review of 
reference genes that can be reliably used to normalizing miRNA expression is lacking to the best of our knowl-
edge. Therefore, the aim of this study was to identify the most suitable candidate miRNAs among those already 
investigated, and then verifying their stability in tissue, plasma and exosomes of both controls and CRC patients.
Results
Literature review. We carried out an electronic search for identifying studies which assessed the stability of 
reference miRNAs in CRC. The initial electronic search allowed to identify a total number of 367 items (Figure 1). 
Overall, 51 review articles and three letters were immediately excluded. Then, 198 articles were also excluded after 
reading titles or abstracts. In particular, 17 of these studies analyzed the effect of dietary or environment on miR-
NAs, 94 were signaling studies, 12 were method comparison studies, 25 did not included CRC patients, 50 studies 
evaluated the association between CRC and functional variants of miRNAs or promoter methylation of target 
miRNAs. Full text was analyzed for study eligibility from the remaining 116 publications. In 109 of these studies 
the purpose was to establish the potential role of miRNAs in CRC diagnosis, prognosis and treatment. When 
reported, target miRNAs have been quantified by using housekeeping miRNA selected from the literature (mostly 
miR-16, RNU6B, RNU48, cel-39, 18SRNA). In some cases the most stably reference miRNA was selected among a 
list of candidates14, 15. In one study miR-451 was chosen as reference gene from high throughput microarray data, 
but the selection method was not reported16. Nine studies were designed to identify reference genes for qPCR 
analysis in CRC patients. Two of these performed the stability study by screening a list of candidate miRNAs 
selected from the literature (U6, miR-16, miR-24, miR-142-3p, miR-19b and miR-192and miR-16, RUN6B and 
miR191) and ought to be excluded15, 17. The remaining 7 studies met our predefined inclusion criteria and were 
finally included in our qualitative review7, 8, 18–22. The most important details of these studies are shown in Table 1, 
along with the list of the candidate reference miRNAs ranked as the most stable by the different research groups.
Figure 1. Flow diagram of the study selection process.
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First 
Author Country
Sample 
type
Discovery phase Validation phase Method used 
to assess 
miRNAs 
stability
Most stably 
expressed 
reference 
miRNAs
Measurement 
method
cases and 
control samples
miR 
selection 
criteria
Candidate 
reference 
genes
Measurement 
method
cases and 
control samples
miR  
selection  
criteria
Candidate 
reference 
miRNAs
Zheng G et 
al. 201318 China serum
Miseq 
sequencing 
(Illumina)-740 
miRNAs
Three pooling 
serum samples: 
-colorectal 
adenocarcinoma 
(n = 30) 
-colorectal 
adenoma 
(n = 25) -healthy 
controls (n = 30)
miRNAs 
(a) having 
at least 50 
copies in the 
three pooling 
samples (b) 
showing no 
differential 
expression 
among 
three groups 
(P > 0.05)
miR-103b 
miR-484 
miR-16-5p 
miR-3615 
miR-18a-3p 
miR-197-3p 
miR-191-5p 
miR-151a-3p 
miR-26a-5p 
miR-4446-3p 
miR-221-3p 
miR-93-5p 
miR-3184-3 
RNU6
RT-qPCR 
Instrument: 
ABI PRISM 
7500 Sequence 
Detection 
System using 
the SYBR 
PrimeScript 
Output: 
average values 
of triplicate Cq
Not matched 
samples 
(n = 125): 
-colorectal 
adenocarcinoma 
(n = 45) 
-colorectal 
adenoma 
(n = 40) -healthy 
controls (n = 40)
(a) the  
miRNAs  
must be  
expressed  
in all  
samples  
(b) mean  
Cq of the  
miRNAs  
must be  
below 35  
(c) no  
evidence  
for  
differential  
expression  
among  
the  
three  
groups  
(P > 0.005)
miR-103b 
miR-484 
miR-16-5p 
miR-3615 
miR-18a-3p 
miR-191-5p 
RNU6
GeNorm and 
NormFinder
-miR-191-
5p -RNU6
Chang KH 
et al. 20108 Ireland tissue
TaqMan 
Human 
MicroRNA 
array 
card(Applied 
Biosystems/
Life 
Technologies) 
-384 miRNAs
Matched 
samples 
(n = 20): 
-tumour tissues 
from patients 
with stage II 
CRC (n = 10) 
-normal tissues 
from patients 
with stage II 
CRC (n = 10)
miRNAs 
whose 
expression 
pattern was 
similar to the 
global mean 
expression
let-7a miR-
26a miR-345 
miR-425 miR-
454 + RNU48 
Z30 miR-16
RT-qPCR 
Instrument: 
7900HT Fast 
Real- Time 
PCR System 
(Applied 
Biosystems) 
Output: 
average values 
of triplicate Cq
Not matched 
samples (n = 74): 
-35 tumour 
specimens -39 
normal tissues
MiRNAs  
with  
equivalent  
expression  
of reference 
genes  
between  
tumour  
and normal 
tissues  
(fold  
change  
cutoff  
of  
logarith-
mised  
Cq = 3)
let-7a miR-
16 miR-26a 
miR-345 
miR-425 
miR-454 
RNU48 Z30
GeNorm and 
NormFinder
-miR-345 
-miR-16
Boisen MK 
et al.201519 Denmark tissue
TaqMan 
Array Human 
MicroRNA 
A + B Cards 
Set version 
3.0 (Applied 
Biosystems/
Life 
Technologies) 
- 754 miRNAs
Not matched 
samples 
(n = 240): 
-mCRC 
(n = 203) 
-healthy controls 
(n = 37)
20 miRNAs 
whose 
expression 
pattern 
correlated 
best with 
global mean 
expression
miR-103a-3p 
miR-152-3p 
miR-132-3p 
miR-27a-3p 
miR-140-5p 
miR-30b-5p 
miR-339-5p 
miR-331-3p 
miR-374a-5p 
miR-652-3p 
miR-335-5p 
miR-185-5p 
miR-30c-5p* 
miR-151-5p 
miR-106b-5p 
miR-199a-3p 
miR-28-5p* 
miR-425-5p 
miR-26a-5p 
miR-24-3p
RT-qPCR 
Instrument: 
7900HT Fast 
Real-Time 
PCR System. 
(Applied 
Biosystems) 
Output: Cq 
values
Not matched 
samples 
(n = 240): 
-mCRC (n = 203) 
-healthy controls 
(n = 37)
MiRNAs  
with  
Cq val-
ues ≤ 32  
and  
with  
a 
260/230 nm 
 absorbance 
ratio ≥ 1.5.  
MiRNAs  
with less  
than 5%  
undeter-
mined  
measure-
ments  
* miR- 
30c-5p  
and  
miR-28 
-5p  
excluded  
because  
they  
were  
in the  
same  
miRNAs  
family  
as other  
miRNAs  
with  
better  
stability  
scores
miR-
103a-3p 
miR-152-3p 
miR-132-3p 
miR-27a-3p 
miR-140-5p 
miR-30b-5p 
miR-339-5p 
miR-331-3p 
miR-
374a-5p 
miR-652-3p 
miR-335-5p 
miR-185-5p 
miR-151-5p 
miR-106b-
5p miR-
199a-3p 
miR-425-5p 
miR-26a-5p 
miR-24-3p
GeNorm 
MiRNAs 
having a 
stability 
value ≥ 0.15
miR-
103a-3p 
miR-152-3p 
miR-132-3p 
miR-27a-3p
Continued
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Author Country
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type
Discovery phase Validation phase Method used 
to assess 
miRNAs 
stability
Most stably 
expressed 
reference 
miRNAs
Measurement 
method
cases and 
control samples
miR 
selection 
criteria
Candidate 
reference 
genes
Measurement 
method
cases and 
control samples
miR  
selection  
criteria
Candidate 
reference 
miRNAs
Hu J et al. 
201420 China plasma
Human 
microRNA 
microarrays 
(Agilent 
Technologies) 
- 723 miRNAs
80 control 
subjects: 
-healthy controls 
(n = 34) --CHB 
patients (n = 21) 
-cirrhosis 
patients (n = 25) 
171 cancer 
patients: -HCC 
(n = 57) -CRC 
(n = 41) -lung 
cancer (n = 73)
MiRNAs 
with (a) Cq 
values ≤ 35 in 
at least 80% 
of samples 
and (b) stable 
value < 0.5 
(by Genorm, 
Normfinder 
and CV) 
(c) miRNas 
controls com-
monly used 
in literature
miR-1225-3p 
miR-1228 
miR-30d 
miR-939 
miR-940 miR-
188-5p miR-
134 + miR-16 
miR-223 let-
7a RNU6B
RT-qPCR 
Taqman 
MicroRNA 
Assays 
(Applied 
Biosystems) 
Output: 
average values 
of triplicate Cq
92 control 
subjects: 
-healthy controls 
(n = 30) -CHB 
patients (n = 31) 
-cirrhosis 
patients (n = 31) 
92 cancer 
patients: -HCC 
(n = 31) -CRC 
(n = 31) -lung 
cancer (n = 30)
MiRNAs 
with (a) Cq 
values ≤ 35 
in at least 
80% of 
samples 
(b) specific 
Taqman 
probe for 
RT-qPCR
miR-
1225-3p 
miR-1228 
miR-30d 
miR-939 
miR-188-5p 
miR-134 
miR-16 
miR-223
GeNorm and 
NormFinder 
miRNAs 
with (a) the 
minimum 
CV value 
and stability 
values (b) 
no statistical 
difference 
between 
early and late 
tumor stages
miR-1228
Rice J et al. 
201521
Kentucky 
(USA) plasma
Microfluidic 
array 
technology 
(Applied 
Biosystems) 
-380 miRNAs
CRC 
patients (not 
characterized)
miRNAs 
expressed 
in > 50% of 
samples and 
miRNAs 
selected from 
the literature
Let-7a Let-
7d Let-7g 
RNU48 RNU6 
miR-520d-5p 
miR-16 miR-
191 miR-223 
miR-484
RT-qPCR 
Step-One 
Plus RT-PCR 
System (Life 
Technologies, 
Carlsbad, CA)
-CRC (n = 20) 
-adenoma 
(n = 11) 
-breast cancer 
(n = 10) -lung 
cancer (n = 10) 
-pancreatic 
cancer (n = 10) 
healthy controls 
(n = 12)
miRNAs 
with 
uniform 
expression 
in all 
samples
RNU6 
miR-520d-
5p miR-16 
miR-191 
miR-223 
miR-484
miRNAs with 
the greatest 
expression 
and the 
narrowest 
SD
-RNU6 
-miR-520d-
5p
Peltier HJ et 
al. 200822
Texas 
(USA) tissue
mirVana 
miRNA 
Bioarrays V1 
(Ambion) 
-287 miRNAs 
RT-qPCR
“horizontal 
scan”: -13 
individual 
normal flash-
frozen human 
tissue RNAs 
-5 flash-frozen 
human tumor 
(including 
CRC)/NAT 
RNA pairs
(a) the miR 
must be high-
ly expressed 
in most, if 
not all, of 
the samples 
(b) the miR 
must be 
consistently 
expressed, as 
measured by 
the modified 
z-score (c) 
only one 
representative 
from a given 
miR family 
should be 
considered 
(d) the miR 
must be a 
target of a 
commercially 
available 
qRT-PCR 
assay at the 
time of the 
work
miR-191 miR-
93 miR-106a 
miR-17–5p 
miR-25 miR-
16 let-7a 
miR-24 miR-
103 miR-99a 
miR-23a miR-
107 + RNU6 
5s rRNA
mirVana 
miRNA 
Bioarrays V1 
(Ambion) -287 
miRNAs RT-
qPCR
“vertical scan”: 
-12 flash-frozen 
human lung 
tumor/NAT RNA 
pairs -16 FFPE 
human lung 
tumor/NAT RNA 
pairs
miRNAs 
with 
uniform 
expression 
in all 
sample 
groups
miR-191 
miR-24 
miR-103 
miR-17–5p 
let-7a mir-
106 miR-16
GeNorm and 
NormFinder
NAT group: 
miR-191 
(or miR-191 
and miR-
25) Tumour 
group: 
miR-103 
Two sample 
groups 
combined: 
miR-191 
and miR-25
Eriksen 
AHM et al. 
20167
Denmark tissue
Microfluidic 
array 
technology- 
OpenArray 
Human 
MicroRNA 
Panel (Life 
Technologies) 
-750 miRNAs
-rectal cancer 
tissue (n = 10) 
-stromal tissue 
(n = 10)
(a) relative 
quantification 
(RQ) close 
to 1:1 (where 
the reference 
biological 
group is 
stromal 
tissue) (b) 
miR detected 
in more than 
70% of all 
replicates of 
all samples 
(c) Cq values 
between 18 
and 28 (d) 
no intentions 
of including 
the miR as 
a target in 
our future 
projects
let-7g miR-
193a-5p 
miR-27a miR-
645 + RNU6
RT-qPCR 
Custom 
TaqMan1Array 
MicroRNA 
Cards (Life 
Technologies) 
Expression 
Suite data-
analysis
2 validation 
studies: -rectal 
cancer tissue 
(n = 25) and 
adjacent stromal 
tissue (n = 25) 
(A) -rectal cancer 
tissue (n = 28) 
and normal 
rectal mucosa 
(n = 28) (B)
miRNAs 
with 
uniform 
expression 
in all 
samples
let-7g miR-
193a-5p 
miR-
27a + RNU6
NormFinder 
miRNA 
with high 
expression 
stability
-let-7g miR-
193a-5p 
miR-27a
Table 1. Characteristics of retrieved studies aimed to identify reference miRNA for CRC experiments 
through high-throughput screening and subsequent qPCR validation. CHB, chronic hepatitis B; CV, 
coefficient of variability; FFPE, fixed paraffin-embedded; HCC, hepatocellular cancer; mCRC, metastatic 
colorectal cancer; NAT, normal adjacent tissue; NPC, nasopharyngeal; RT-qPCR, real-time quantitative 
reverse-transcription polymerase chain reaction; SD, standard deviation.
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MiRNAs selection. Because miRNAs function through post-transcriptional gene repression, we retrieved 
from miRTarBase23 the experimentally validated target genes of candidate reference miRNAs selected from the 
literature: hsa-let-7g, hsa-miR-103a, has-miR-1228, hsa-miR-16, hsa-miR-132, hsa-miR-152, has-miR-191, 
hsa-miR-193, hsa-miR-25, hsa-miR-27a, hsa-miR-345 and hsa-miR-520d. Only miRNA-target interactions val-
idated by western blot analysis or Luciferase report assay were used for the in silico analysis. Weak functional 
miRNA-target interactions, identified by high-throughput sequencing technologies, were excluded. Altogether, 
these 12 miRNAs cumulatively targeted 178 genes, 21 of which were targeted by multiple miRNAs (ranging from 
2 to 4), thus enhancing the total number of miRNA:mRNA interactions to 202 (Additional file 1). To gain a spe-
cific insight in cancer context, we parsed the target genes of candidate miRNAs and compared them against the 
list of ‘tumour suppressor genes’ or ‘oncogenes’, respectively (retrieved from the UniProt Knowledgebase24. See 
Methods section for details).
Seven out of 12 miRNAs target at least two oncogene or tumor suppressor gene. More specifically, miR-16 
showed the largest number of onco/tumor suppressor genes (n = 13) followed by miR-27a (n = 8), let-7g (n = 6), 
miR-25 (n = 6), miR-152 (n = 4), miR-132 (n = 3) and miR-103a (n = 2). Oncogenes with multiple miRNA 
interactions were BCL1 (miR-16, miR-27a and miR-152), KRAS (let-7g, miR-16, miR-27a and miR-152), BMI-1 
(let-7g, miR-16), MYB (miR-103a, miR-16). Tumor suppressor genes with multiple miRNA interactions were: 
PTEN (miR-103a, miR-25), RECK and TP53 (mir-16, miR-25). The remaining 5 candidate miRNAs (miR-191, 
miR-193a, miR-345, miR-520d and miR-1228), showing no interactions with any known oncogene or tumor 
suppressor gene, were selected for the experimental study. The spike in control cell-39 was also included for sub-
sequent analyses due to its broad use in literature as external reference control.
Expression levels of candidate reference miRNAs. The six candidate reference miRNAs displayed a 
wide expression range, with Cq values comprised between 15.0 and 33.9 in the entire study sample. The expres-
sion levels of each miRNA in the three different matrices is shown in Table 2. Except miR-345, the expression val-
ues of which were relatively low in exosomes and moderately abundant in both plasma and tissue samples, all the 
other miRNAs displayed median Cq values sufficiently homogenous between the three matrices. The most highly 
expressed miRNA was miR-191, which exhibited a median Cq values of 22.4 in exosome, 22.9 in plasma and 21.9 
in tissue samples, respectively. In contrast, other miRNAs were found to be less abundant; for example miR-520d 
displayed a median Cq values of 30.3, 30.1 and 29.7 in exosome, plasma and tissue samples, respectively, whereas 
miR-345 displayed a median Cq value of 30.5 in exosomes.
The range of Cq values for miR-191 was rather broad in both exosome and plasma samples, with ∆Cq values 
above 15 cycles. High ∆Cq were also found for miR-193 in exosomes (14.3 cycles). All the other miRNAs dis-
played narrow Cq range in all sample sets. According to the ∆Cq values, the most stably expressed miRNAs were 
miR-1228 in exosomes, miR-520d in plasma samples and miR-193 in tissues (Table 2). As shown in Fig. 2, the 
box - plot analysis does not reveal significant differences of expression levels of all but one candidate reference 
miRNAs (Figure 2). As predicted from analysis of ∆Cq, the expression level of miR-191 was higher in exosome 
and plasma samples from CRC patients than in those of healthy controls (p = 0.015 and p < 0.0001 respectively). 
Due to this different expression level, miR-191 was excluded from further stability analysis in exosome and 
plasma samples.
Expression stability of candidate reference miRNAs. The variable stability of the selected reference 
genes was evaluated using NormFinder and BestKeeper algorithms. The rankings of reference genes by analysis 
of stability value generated by the two algorithms are summarized in Tables 3 and 4. Lower stability values charac-
terize greater stability. The summarized data indicates that the NormFinder and BestKeeper algorithms produce 
similar rank orders for candidate reference miRNAs expression stability.
Despite the presence of modest inconsistencies due to differences in calculation methods between the two 
algorithms, the results obtained with BestKeeper were in accord with those obtained using NormFinder, thus 
confirming miR-520d at the top of the rank in all three matrices and miR-1228 and miR-345 as the second most 
stable miRNAs.
Effect of suitable reference genes on relative expression of target miR-1290. The expression of 
miR-1290 in exosome, plasma and tissue of CRC patients and heathy controls was evaluated using single candi-
date reference gene as well as different combination of miR-1228, miR-345, miR-520d used for normalization. 
As shown in Fig. 3, all combinations allowed to identify a significant up-regulation of miR-1290 in exosome, 
Exosome Plasma Tissue
miRNAs Median (range) ∆Cq Median (range) ∆Cq Median (range) ∆Cq
cell-39 25.6 (19.8–28.3) 8.5 24.3 (20.2–29.0) 8.8 23.8 (21.4–29.0) 7.6
mir-345 30.5 (26.4–33.0) 6.6 25.5 (21.8–30.2) 8.4 24.6 (22.9–27.4) 5.3
mir-1228 28.2 (26–30.7) 4.7 27.9 (24.9–29.8) 4.9 25.3 (21.9–29.5) 7.6
mir-191 22.4 (16.3–33.9) 17.6 22.9 (16.1–31.9) 15.9 21.9 (18.1–27.4) 9.4
mir-193 25.5 (19.1–33.4) 14.3 21.3 (17.2–25.2) 8 23.0 (19.9–25.3) 5.4
mir-520d 30.3 (28.1–33.7) 5.6 30.1 (27.9–32.4) 4.5 29.7 (26.2–31.7) 5.5
Table 2. Expression levels of candidate reference miRNAs in different matrixes from CRC patients and healthy 
controls.
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plasma and tissue samples (all p < 0.005). The combination of miR-520d and miR-1228 led to the greatest differ-
ence in miR-1290 relative expression between CRC samples and controls in all the three matrices (p = 0.0002 for 
exosome, p = 0.0001 for plasma and 0.0051 for tissue). Conversely, no difference in miR-1290 expression could be 
detected when single, less stable reference genes were used for normalization (supplementary Figure 1).
Figure 2. Expression levels of candidate reference miRNAs. Box and whisker plot displaying the Cq values 
for each putative reference miRNA. There is no significant difference in the expression level of cell-39, miR-
345, miR-1228, miR-193 and miR-520d, between tumour and normal samples in exosomes, plasma and tissue 
samples. miR-191 showed a significant difference between exosome and plasma samples from CRC and healthy 
controls (p = 0.015 and p < 0,0001).
Rank
Exosome Plasma Tissue
Gene name
Stability 
value Gene name
Stability 
value Gene name
Stability 
value
1 miR-520d 0,260 miR-520d 0,227 miR-520d 0,191
2 mir-1228 0,277 mir-193 0,352 mir-1228 0,239
3 miR-345 0,320 miR-345 0,431 miR-345 0,242
4 cel-39 0,481 mir-1228 0,465 mir-193 0,263
5 mir-193 0,572 cel-39 0,485 miR-191 0,340
6 cell-39 0,347
Best combination miR-520d, miR-1228 0.165 miR-345, miR-520d 0.223 miR-345, miR-520d 0.151
Table 3. Ranking of candidate reference miRNAs using NormFinder algorithm.
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Discussion
Several lines of evidence suggest that the assessment of miRNAs not only hold great promise for the diagnosis, 
prognosis, prognostication and therapeutic follow-up of patients with CRC, but is can also be proposed as a 
potential tool for developing new cancer drugs25. However, appropriate use of miRNAs requires to clearly define 
the precise dysregulation of the different miRNAs in various disease states.
The normalization of miRNAs expression by using reference genes is an essential component of a reliable 
qPCR assay. This approach enables reducing the bias attributable to variations in extraction, reverse-transcription 
Rank
Exosome Plasma Tissue
Gene name Stability value Gene name Stability value Gene name Stability value
1 mir-1228 1.02 mir-520d 0.96 mir-345 0.82
2 mir-520d 1.25 mir-1228 1.22 mir-520d 0.93
3 mir-345 1.76 mir-193 1.53 mir-193 1.03
4 cell-39 1.87 mir-345 1.63 mir-1228 1.16
5 mir-193 2.39 cell-39 1.79 cell-39 1.49
6 mir-191 1.59
Table 4. Ranking of candidate reference miRNAs using BestKeeper algorithm.
Figure 3. Effect of reference gene choice on relative expression of target miR-1290. By using different 
combinations of selected reference miRNAs the difference in miR-1290 expression between CRC and control 
samples always resulted significantly different (p < 0.005 for all).
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yield and amplification efficiency, so allowing the comparison of miRNA expression levels among different sam-
ples as well as the identification of longitudinal changes over time.
Although it is increasingly recognized that normalization of miRNA expression is a crucial aspect for obtain-
ing reliable data, and that the use of inappropriate reference genes for normalization may generate unreliable or 
misleading results, putative housekeeping genes are still used as normalizers with no appropriate validation26. 
The current guidelines clearly recommend to identify stably expressed genes in each experimental system27, so 
generating a steady increase of studies aimed to dissect suitable normalizers in different pathological conditions 
and matrices, by using high throughput analyses. Although it is no longer accepted that certain reference genes 
are stable by convention, thanks to increasing understanding of miRNAs biology it is reasonable to assume that 
certain genes can be considered unstable a priori in a specific pathological condition. For example, owing to the 
well-established involvement of miR-16 in the pathogenesis of human cancer28, and due to its widely demon-
strated down regulation in different malignancies29–34, it is now widely accepted that the conventional use of 
miR-16 as a normalizer should be abandoned in cancer research. A more rational approach for searching stable 
miRNAs within defined experimental protocol may start with candidate reference miRNAs already identified 
in the literature instead from using information obtained by means of high throughput techniques, as recently 
suggested by Schwarzenbach13.
One of the aims of this study was to perform a systematic review of the current scientific literature for identi-
fying reliable evidence about potential reference miRNAs in CRC detected with high throughput technologies. 
Seven studies finally met our inclusion criteria. Due to heterogeneity of experimental design, sample matrices 
and population cohorts, a number of different candidates miRNAs have been identified. The only exception was 
miR-191, which was classified as the most stably expressed miRNAs by two independent research groups18, 22. The 
second part of our study encompassed the analysis of 12 miRNAs, which have been proposed as candidate refer-
ence miRNAs by the different studies. More specifically, we performed in silico analysis to test for their potential 
involvement in cancer biology. Among the number of bioinformatics tools available to search for miRNA-mRNA 
interaction35, we decided to perform a simple comparison between two databases. The former, miRTarBase, pro-
vides a manually based coxllection of current validated miRNA-target interactions (MTIs), whereas the latter, 
UniProTKB, contains a comprehensive list of known oncogenes and tumor suppressor genes. In order to exclude 
the largest number of potentially unstable miRNAs, matched data were analyzed by a conservative approach, so 
excluding from further analysis those miRNAs which had at least one oncogene or tumor suppressor gene among 
their validated targets. Seven miRNAs were so excluded (miR-16, miR-27a, let-7g, miR-25, miR-152, miR-132 
and miR-103a). All these short RNA fragments target at least two onco/tumor suppressor genes and at least one 
gene involved in the pathogenesis of CRC (Additional file 2)4, 36, 37. Notably, the analysis on miR-16 revealed that, 
among the 52 putative targets, 11 were oncogenes or tumor suppressor genes (9 and 4 respectively). Four of these 
were found to have a definite role in the pathogenesis of CRC4, 36, 37. These are: KRAS, CCND1, RAF and TP53.
The miR-191, miR-193, miR-1228, miR-520d and miR-345 were instead miRNAs for which a significant asso-
ciations with either onco- nor tumor-suppressor genes could not be proven. The performance of these candidate 
miRNAs, along with the spike in cel-39, was hence tested in the experimental part of our study. We performed, for 
the first time, the simultaneous evaluation of miRNAs expression levels and stability in CRC patients and healthy 
controls, using different biological matrices such as exosomes, plasma and CRC tissue samples.
The Cq values of C. elegance miR-39, which was used as a spike-in RNA control to define the quality control 
and confidence of qPCR performance, were highly reproducible among samples, displaying a median (standard 
deviation) SD of 2.1 across different biological matrices, so indicating that our data can be considered relatively 
robust.
According to the analysis of ∆Cq and the results obtained from NormFinder and Bestkeeper, miR-193 was 
found to be rather stable in plasma, and even more stable in tissue samples. Nevertheless, this miRNA displayed 
high ∆Cq and low stability values in exosomes, so that its use as reference miRNA may be discouraged in this 
matrix. Interestingly, we found that miR-191 was over-expressed in exosome and plasma sample of CRC patients 
compared to the exosomes and plasma of healthy controls. A broad ∆Cq was found for the analysis of miR-191 
in both plasma samples and exosomes. The analysis of miR-191 Cq values by the two algorithms revealed low 
stability values in all the matrices. These results, rather consistent among tissue samples, plasma and exosomes, 
indicate that miR-191 may be implicated in the pathogenesis of CRC. Functional miRNA-cancer target interac-
tions have not been earlier validated as with our in silico analysis, which failed to show any match with putative 
onco-targets in current databases. However, recent studies indicate that miR-191 may be strongly implicated in 
cancer biology38. According to our experimental data, miR-191 was found to be over expressed in more than 
20 malignancies (including CRC), and this evidence is consistent with its classification as oncogenic miRNA. 
In CRC, anti-miR-191 attenuates invasiveness, suppresses proliferation and induces apoptosis by restoring the 
expression of tissue inhibitor of metalloprotease 3 (TIMP3), which is a potential target of this miRNA39.
Our combined analyses finally allowed to identify miR-520d, miR-345 and miR-1228 as the top three refer-
ence miRNAs in our study cohort. These miRNAs have been previously validated as suitable reference miRNAs 
in CRC tissue (miR-345) and plasma samples (mir-1228 and miR-520d)8, 20, 21. Therefore, their use in biological 
matrices different from those used in the primary studies need further evaluations having been tested here in a 
small sample set. However, the consistent stability displayed by these miRNAs across three different matrices 
prompt for their classification as “true reference miRNAs” in CRC, a conclusion that is also supported by their 
non-functional role in CRC as emerging from the current scientific literature.
miR-1228 was proven to be extensively involved in metabolism-related signal pathways and organ morphol-
ogy. An unstable expression of this miRNA during development of the hematological system was also found by 
functional network analysis, so explaining its steady expression in blood20. miR-345 was found to play a major 
role in modulation of monocyte-related inflammatory response, through regulation of RelA transcription fac-
tor40. This miRNA is also involved in suppressing prostate cancer proliferation, invasion and migration, probably 
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by downregulation of Smad141. Human miR-520d is currently consider a minor miRNA, involved in HER2/neu 
receptor-related and osteoblast differentiation42. A recent study highlighted a key role of miR-520d in transfor-
mation of hepatoma cells into normal/benign phenotypes43.
By using different combination of these selected reference genes, a significant difference in miR-1290 expres-
sion was always detected in the three matrices. Contrarily, the results of target miR-1290 quantification were 
inconsistent when single, less stable miRNAs were used for normalization, thus highlighting the importance of 
selecting appropriated normalizers and confirming previous evidence that the use of more than one reference 
genes may enhance the accuracy of target miRNA quantitation44, 45.
Taken together, our results support the current opinion that the era of searching for universal reference miR-
NAs may be over44, 45. The cases of miR-16 and miR-191 presented here is a clear clue that the attitude to select a 
priori universal normalizers for miRNAs should be replaced in favor of adopting standardized methods for select-
ing case-specific normalizers. Although the application of high throughput screening is still considered the most 
effective benchmark, alternative and less expensive strategies exist44, 45. The approach used in our study has taken 
great benefit from the vast information gathered in over 20 years of investigating functional roles of miRNAs in 
both physiological and pathological states, as well as from advances in miRNAs expression studies and technol-
ogies. It consists of a series of sequential steps, as follows: (i) rigorous analysis of the literature for identifying 
candidate normalizers, (ii) analysis of the main interactions of miRNA-target through bioinformatics tools, (iii) 
elimination of miRNAs known to be involved in the pathogenesis of the study-specific disease, (iv) experimental 
verification of stability of candidate miRNAs within the specific study cohort and, (v) use of validated algorithms 
for final selection of the more suitable miRNAs for each experimental protocol.
Our approach for identification and verification of reference miRNAs in different biological matrices will 
hopefully represent a significant advancement to be used in future studies on CRC, but may also offer meaningful 
opportunities for other diseases and experimental conditions.
Methods
Systematic review. We carried out an electronic search for identifying studies which have assessed the 
stability of reference miRNAs in CRC. The preliminary search was performed in Medline (PubMed interface) 
from 2001 to March 7, 2016 without language restriction. The following keywords were used: “miRNA” AND 
“normaliz*” OR “stability” OR “control” OR “housekeeping” OR “reference” AND “colorectal” OR “colon” AND 
“cancer” OR “neoplasm” OR “malignancy”. We selected original articles of both observational studies and clinical 
trials when published in full text or full access to original data could be obtained. We hence included those studies 
in which the authors (i) selected the most stably expressed miRNAs from high-throughput technology-based 
miRNA expression profiling in a “discovery phase”(ii) assessed the stability of selected miRNAs by qPCR analysis 
in a “validation phase”. Two reviewers (ED and MM) independently evaluated titles and abstracts of the different 
publications to assess eligibility. A flow diagram of the study selection process is shown in Fig. 1.
Full data were extracted from all the publications meeting our inclusion criteria. The following information 
was also retrieved: first author’s last name, year of publication, country of origin; for both discovery and the vali-
dation studies: measurement method, analysis of data, source and number of case and control samples.
In silico analysis. The target genes of candidate reference miRNAs selected from the literature were retrieved 
from miRTarBase23 (available at http://mirtarbase.mbc.nctu.edu.tw/), which includes the most updated and com-
prehensive information of experimentally validated miRNA-target interactions (last update, Sept. 15, 2015). The 
targets of the reference miRNAs were then compared with the list of human ‘oncogenes’ and ‘tumour suppressor 
genes’ retrieved from the UniProt Knowledgebase, a central hub for collection of functional information on pro-
teins with accurate, consistent and extensive annotation24. Of the two UniProtKB sections, we selected that merg-
ing experimental results, computed features and scientific conclusions (UniProtKB/Swiss-Prot) with high quality 
manually-annotated and nonredundant records (last update June 21, 2016). The other, based on non-reviewed 
automatically annotated records (UniProtKB/TrEMBL) was not considered (Keyword: “Proto-oncogene [KW-
0656]”; http://www.uniprot.org/uniprot/?query = KW-0656&sort = score), (Keyword: “Tumor suppressor [KW-
0043]”; http://www.uniprot.org/uniprot/?query = KW-0043&sort = score). MiRNAs having no targets in both 
oncogenes and tumor suppressor genes were finally selected for the experimental verification study.
Experimental study. Patients and specimens. The CRC specimens including tumor tissue, normal mucosa, 
plasma and exosome were obtained from 20 patients undergoing surgical resection at the University Hospital of 
Verona between 2010 and 2011 (mean age, 60 ± 13.5 years; 14 males and 6 females). Plasma and exosome were 
also obtained from 20 healthy volunteers enrolled from the staff of the local laboratory (mean age, 57.3 ± 9.2 
years; 11 males and 9 females). Paired specimens of tumor and adjacent normal mucosa were obtained during 
surgical procedure, immediately frozen in liquid nitrogen and stored at −80 °C. According to the American Joint 
Committee on Cancer (AJCC) staging system46, 8 patients were at stage II, 8 patients at stage III, and 4 at stage 
IV. Only patients with primary colorectal adenocarcinomas untreated with neoadjuvant radio-chemotherapy 
were included in this study. Blood specimens were collected before intervention. Clinical information was 
accessed through hospital medical records. The study protocol was approved by the University Hospital of Verona 
Institutional Review Board. Informed consent was obtained from all patients prior to the collection of sam-
ples. Specimens and all experimental procedures were handled and carried out in accordance with the approved 
guidelines.
Extraction of exosomal, plasma and tissue RNA and conversion into cDNA. Isolation of total exosome and 
pretreatment of plasma and tissue specimens was performed according to standard procedures and as previ-
ously described47–49. RNA was extracted from plasma and exosome specimens with mirVana PARIS kit (Life 
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Technologies, New York, USA) and Total Exosome RNA and Protein Isolation Kit (Life Technologies, New York, 
USA). Total RNA was isolated from normal mucosa and tumor tissues using a commercially available preparation 
(TriReagent; Molecular Research Center, Inc., Cincinnati, OH, USA). A detailed description of these procedures 
is available in the Supplementary methods.
After extraction, the RNA was quantified in triplicate on a NanoDrop ND-1000 Spectrophotometer (Thermo 
Scientific, Wilmington, Delaware, USA). The mean concentration of three measurements within the same RNA 
specimen was used to calculate the input total RNA for RT-qPCR. Reverse transcription was performed by the 
TaqMan Advanced miRNA cDNA synthesis Kit (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). 
Briefly, 2 μl of total RNAs (corresponding to 10 ng of RNA), including miRNAs, were extended by a poly(A) 
tailing reaction using 0,06 U poly(A) polymerase enzyme and 1 mM of ATP. MiRNAs were then modified by 
lengthening the 5′ end by adaptor ligation. The miRNA with a poly(A) tail and adaptor was converted into cDNA 
through reverse transcription. Each reverse transcriptional reaction solution contained 1.2 μl of 25 mM dNTPs, 
3 μl of 10X Reverse Transcriptase, 6 μl of 5x Reverse Transcription Buffer, 1.5 μl of 20 × Universal RT primer, 3.3 μl 
nuclease-free water. The reaction was carried out at 42 °C for 15 min and 85 °C for 5 min, using AB 2720 (Thermo 
Scientific, Wilmington, Delaware, USA). The samples of cDNA were stored at −20 °C for future usage.
Quantitative real-time PCR. Due to the low levels of some exosomal miRNAs, a preamplification step of cDNA 
was included in all quantifications. Five μl cDNA were preamplified in 25 μl of 2X miR-amp master mix, 2.5 μl 
of 20 × miR-amp primer mix and 17.5 μl nuclease-free water. PCR was run on AB 2720 (Thermo Scientific, 
Wilmington, Delaware, USA): 1 cycle at 95 °C for 5 min, 24 cycles at 95 °C for 3 s, 60 °C for 30 s and a terminal 
cycle at 99 °C for 5 min. The PCR products at the end of the run were diluted 1:7 in 0.1X TE buffer pH8.0 and 
stored at −20 ◦C. For quantitative real-time PCR, the miRNA-specific TaqMan™ Advanced miRNA assays Kit 
(Applied Biosystems Life Technologies, Carlsbad, CA, USA) for cell-39, miR-191, miR-193, miR-345, miR-520d 
miR-1228 and for the target oncogenic miR-1290 were used. Since probes for the small noncoding RNA RNU6 
were not yet included in the Advanced kit, this small internal control was excluded from the analysis. In a 20 
μl-reaction, 5 μl preamplified cDNA diluted was mixed with 10 μl 2X Fast Advanced Master mix, 1 μl 20 × miRNA 
specific TaqMan Advanced miRNA Assay and 4 μl nuclease-free water. Quantitative real-time PCR reaction was 
performed at 95 °C for 20 s and in 40 cycles at 95 °C for 3 s and 60 °C for 30 s, on a AB7500 Real Time System 
(Applied Biosystems Life Technologies, Carlsbad, CA, USA).
Statistical analysis. The statistical analysis was performed using the Graph Pad Prism software package, 
version 5.0 (GraphPad software Inc., La Jolla,CA, USA). Distribution of continuous data was determined using 
the D’Agostino & Pearson omnibus test. The quantification cycle (Cq) value, which is inversely proportional to the 
target mRNA abundance, was used to estimate the level of gene expression. The mean of three repeated measures 
per sample was finally reported.
The expression levels of the candidate reference miRNA in patients and controls was assessed using box-plot 
analysis50. The Mann-Whitney test was used to assess the difference in relative expression levels of miRNAs 
between patients and controls. The expression variation range of Cq values (ΔCq) was calculated using the for-
mula ΔCq = Cqmax − Cqmin. Because the cDNA templates for the different samples were reverse transcribed from 
the same amount of total RNA, we used the ΔCq as the first parameter to assess expression stability of candidate 
reference miRNAs. A narrow range of Cq values indicated more stable expression. The expression stability was 
then evaluated by using two algorithms, i.e., NormFinder51 and BestKeeper52. Since these models assume that 
candidates should be stably expressed in different experimental groups, only miRNAs showing no statistically 
different expression between CRC and control samples were included in our analysis.
Briefly, the NormFinder uses an ANOVA-based model to separate the analysis of sample subgroups, estimates 
both the intra- and the intergroup expression variations, and finally calculates the stability value of a candidate 
gene. The program operates with a Microsoft Excel platform that automatically calculates the stability value for all 
candidate normalization genes containing any number of samples arranged in any number of groups. The most 
stable gene expression is indicated by the lowest average expression stability value. For NormFinder analyses, Cq 
values were transformed to relative quantities using the formula 2−∆Cq, where ∆Cq = Cq of the gene in selected 
sample - minimum Cq of corresponding gene in the experiment. The sample with minimum Cq or maximum 
expression was used as the calibrator with a set value of 1.
Bestkeeper (http://gene-quantification.com/bestkeeper.html) determines the geometric mean and standard 
deviation (SD) of Cq values of the candidate genes by pairwise correlation analyses. The lowest SD value indicates 
the most stable reference miRNA expression. Finally, the consensus rankings of the candidate reference miRNAs 
were determined according to the geometric rank means from the two analyses.
The relative expression of the target miR-1290 normalized to one or more reference candidates was also 
determined using the 2−∆Cq method. The choice of this case study target miRNA was based on a recent find-
ing according to which miR-1290 was found to be strongly up-regulated in plasma of patients with CRC53. The 
Mann-Whitney test was used to compare the expression of miR-1290 among the clinical groups.
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